2025
Effects of Long-Term Cocaine Self-Administration on Kappa Opioid Receptors in Socially Housed Cynomolgus Monkeys as Assessed with PET Imaging and Neuronally Derived Exosomes
Johnson B, Allen M, Nader S, Sai K, Kumar A, Su Y, Singh S, Li S, Huang Y, Deep G, Nader M. Effects of Long-Term Cocaine Self-Administration on Kappa Opioid Receptors in Socially Housed Cynomolgus Monkeys as Assessed with PET Imaging and Neuronally Derived Exosomes. Biological Psychiatry 2025 PMID: 40054763, DOI: 10.1016/j.biopsych.2025.02.900.Peer-Reviewed Original ResearchLong-term cocaine self-administrationKappa-opioid receptorsCocaine self-administrationSelf-administrationKappa opioid receptor availabilityPeripheral measuresSocially housed monkeysOpioid receptorsCocaine intakeCocaine SAIntravenous cocaineCocaine misuseBrain regionsCocainePET imagingCynomolgus monkeysSocial rankPET studiesPharmacological interventionsMonkeysPET scansBrainBlood samplesDominant femalesSocialCorrection: Quantifying VMAT2 target occupancy at effective valbenazine doses and comparing to a novel VMAT2 inhibitor: a translational PET study
Terry-Lorenzo R, Albrecht D, Crouch S, Wong R, Loewen G, Giri N, Skor H, Lin K, Sandiego C, Pajonas M, Rabiner E, Gunn R, Russell D, Haubenberger D. Correction: Quantifying VMAT2 target occupancy at effective valbenazine doses and comparing to a novel VMAT2 inhibitor: a translational PET study. Neuropsychopharmacology 2025, 50: 719-719. PMID: 39843851, PMCID: PMC11845734, DOI: 10.1038/s41386-025-02055-w.Peer-Reviewed Original ResearchQuantifying VMAT2 target occupancy at effective valbenazine doses and comparing to a novel VMAT2 inhibitor: a translational PET study
Terry-Lorenzo R, Albrecht D, Crouch S, Wong R, Loewen G, Giri N, Skor H, Lin K, Sandiego C, Pajonas M, Rabiner E, Gunn R, Russell D, Haubenberger D. Quantifying VMAT2 target occupancy at effective valbenazine doses and comparing to a novel VMAT2 inhibitor: a translational PET study. Neuropsychopharmacology 2025, 1-9. PMID: 39757283, DOI: 10.1038/s41386-024-02046-3.Peer-Reviewed Original ResearchVesicular monoamine transporter type 2Treatment of tardive dyskinesiaPositron emission tomographyVesicular monoamine transporter type 2 inhibitorsTarget occupancyTreatment of chorea associated with Huntington's diseaseTreatment of TDChorea associated with Huntington's diseaseCentral nervous systemTardive dyskinesiaVMAT2 inhibitorsValbenazineClinical developmentEffect sizeAssociated with efficacyPET studiesEmission tomographyGold standard biomarkerDosing regimensClinical benefitDaily doseHuntington's diseaseActive metabolitePlasma concentrationsAcceptable dose
2024
P2X 7-receptor binding in new-onset and secondary progressive MS – a [11C]SMW139 PET study
Lehto J, Aarnio R, Tuisku J, Sucksdorff M, Koivumäki E, Nylund M, Helin S, Rajander J, Danon J, Gilchrist J, Kassiou M, Oikonen V, Airas L. P2X 7-receptor binding in new-onset and secondary progressive MS – a [11C]SMW139 PET study. EJNMMI Research 2024, 14: 123. PMID: 39636350, PMCID: PMC11621262, DOI: 10.1186/s13550-024-01186-3.Peer-Reviewed Original ResearchPerilesional rimTracer bindingDisability progressionMS patientsMS brainsLesion rimWhite matterProgressive MS patientsPro-inflammatory microgliaRelapsed patientsSmoldering inflammationT1 lesionsMales compared to femalesNew-onsetProgressive patientsTracer uptakeParent tracerP2XDisease durationProgressive MSHealthy controlsPatientsPET studiesPerilesional areaFree fractionDoes seasonal variation affect the neuroimmune system? A retrospective [11C]PBR28 PET study in healthy individuals
Ibrahim W, An J, Yang Y, Cosgrove K, Matuskey D. Does seasonal variation affect the neuroimmune system? A retrospective [11C]PBR28 PET study in healthy individuals. Neuroscience Letters 2024, 828: 137766. PMID: 38583505, PMCID: PMC11073647, DOI: 10.1016/j.neulet.2024.137766.Peer-Reviewed Original ResearchConceptsTranslocator protein levelsPositron emission tomographyNeuroimmune systemHealthy individualsHuman studiesPositron emission tomography scanTranslocator proteinTest-retest variabilityBrain TSPO levelsVolume of distributionPositron emission tomography imagingBrain regionsCentral nervous systemTranslocator protein expressionGene polymorphismsCell markersHealthy subjectsTSPO levelsInterindividual variabilityNeuropsychiatric disordersEmission tomographyPET studiesNervous systemMonthsNo significant effect
2023
Synaptic PET Imaging in Neurodegeneration
Chen M, Matuskey D, Finnema S, Carson R. Synaptic PET Imaging in Neurodegeneration. 2023, 157-167. DOI: 10.1007/978-3-031-35098-6_10.ChaptersAlzheimer's diseaseSynaptic densityProgressive supranuclear palsySynaptic vesicle glycoprotein 2ALarge patient cohortPositron emission tomography (PET) biomarkersInitial PET studiesMultiple neurodegenerative diseasesSupranuclear palsyCorticobasal degenerationLewy bodiesPatient cohortSynapse densityTomography biomarkersClinical valueParkinson's diseaseNeurological diseasesBrain regionsFrontotemporal dementiaPET studiesDiseaseNeurodegenerative diseasesHuntington's diseaseMultiple centersSynaptic vesicle membraneLinking resting-state network fluctuations with systems of coherent synaptic density: A multimodal fMRI and 11C-UCB-J PET study
Fang X, Volpi T, Holmes S, Esterlis I, Carson R, Worhunsky P. Linking resting-state network fluctuations with systems of coherent synaptic density: A multimodal fMRI and 11C-UCB-J PET study. Frontiers In Human Neuroscience 2023, 17: 1124254. PMID: 36908710, PMCID: PMC9995441, DOI: 10.3389/fnhum.2023.1124254.Peer-Reviewed Original ResearchSynaptic densityRSN activityResting-state network connectivityRSN functional connectivityAnterior default mode networkJ PET studyResting-state fMRIBrain functional organizationDefault mode networkHealthy adult participantsExecutive control networkRSN connectivityFunctional organizationPsychiatric disordersMedial prefrontalSalience networkPET studiesFunctional connectivityHealthy agingFractional amplitudeLow-frequency fluctuationsNeurophysiological linkSynaptic architectureAdult participantsDefault-mode activityExamining mGlu5 Receptor Availability as a Predictor of Vulnerability to PTSD: An [18F]FPEB and PET Study in Male and Female Rats
Asch R, Fowles K, Pietrzak R, Taylor J, Esterlis I. Examining mGlu5 Receptor Availability as a Predictor of Vulnerability to PTSD: An [18F]FPEB and PET Study in Male and Female Rats. Chronic Stress 2023, 7: 24705470231215001. PMID: 38024327, PMCID: PMC10666551, DOI: 10.1177/24705470231215001.Peer-Reviewed Original ResearchPost-traumatic stress disorderReceptor availabilityFemale ratsPathophysiology of PTSDFootshock exposureMetabotropic glutamate receptor 5Recent preclinical findingsGlutamate receptor 5Positron emission tomographyPreclinical findingsClinical findingsFe ratsReceptor 5Lower baselineEmission tomographyGreater riskPET studiesRatsStress disorderDifferential involvementPassive copingSex differencesMalesPTSD susceptibilityBaseline
2022
P204. Role of Kappa Opioid Receptor Availability in Borderline Personality Disorder and Suicidal Behavior: Preliminary Results From an in Vivo [11C]EKAP PET Study
Davis M, Wilson O, DeBonee S, Nabulsi N, Matuskey D, Esterlis I. P204. Role of Kappa Opioid Receptor Availability in Borderline Personality Disorder and Suicidal Behavior: Preliminary Results From an in Vivo [11C]EKAP PET Study. Biological Psychiatry 2022, 91: s169-s170. DOI: 10.1016/j.biopsych.2022.02.438.Peer-Reviewed Original ResearchPET Imaging of Synaptic Density: Challenges and Opportunities of Synaptic Vesicle Glycoprotein 2A PET in Small Animal Imaging
Toyonaga T, Fesharaki-Zadeh A, Strittmatter SM, Carson RE, Cai Z. PET Imaging of Synaptic Density: Challenges and Opportunities of Synaptic Vesicle Glycoprotein 2A PET in Small Animal Imaging. Frontiers In Neuroscience 2022, 16: 787404. PMID: 35345546, PMCID: PMC8957200, DOI: 10.3389/fnins.2022.787404.Peer-Reviewed Original ResearchAnimal modelsPET imaging studiesPET imagingImaging studiesSynaptic vesicle glycoprotein 2ADisease animal modelsOngoing clinical investigationsDifferent injection routesSynaptic densityClinical investigationPharmacological effectsRodent brainNovel interventionsInjection routeNeurodegenerative disordersNeuropsychiatric diseasesPET studiesBrainMultiple diseasesPET centersDiseaseInjectable volumeImagingSmaller brainsPET
2021
Brain target occupancy of LY3372689, an inhibitor of the O‐GlcNAcase (OGA) enzyme, following administration of single and multiple doses to healthy volunteers
Kielbasa W, Shcherbinin S, Goldsmith P, Phipps K, Biglan K, Mancini M, Russell D, Constantinescu C, Gunn R, Nuthall H, Mergott D, Lowe S, Collins E. Brain target occupancy of LY3372689, an inhibitor of the O‐GlcNAcase (OGA) enzyme, following administration of single and multiple doses to healthy volunteers. Alzheimer's & Dementia 2021, 17 DOI: 10.1002/alz.057774.Peer-Reviewed Original ResearchHealthy volunteersEnzyme occupancyPET scansSingle doseMultiple-dose clinical studiesPost-dose intervalPositron emission tomography radioligandBaseline PET scanLonger clinical trialsTarget occupancyTau-related diseasesMultiple dosesMultiple dosingClinical trialsPlasma pharmacokineticsClinical studiesEfficacy trialsSD studiesDose selectionTomography radioligandEnzyme inhibitorsPotential treatmentAlzheimer's diseasePET studiesTarget engagementPreclinical characterization of [18F]T-008, a novel PET imaging radioligand for cholesterol 24-hydroxylase
Koike T, Constantinescu CC, Ikeda S, Nishi T, Sunahara E, Miyamoto M, Cole P, Barret O, Alagille D, Papin C, Morley T, Fowles K, Seibyl J, Tamagnan G, Kuroita T. Preclinical characterization of [18F]T-008, a novel PET imaging radioligand for cholesterol 24-hydroxylase. European Journal Of Nuclear Medicine And Molecular Imaging 2021, 49: 1148-1156. PMID: 34651220, PMCID: PMC8921165, DOI: 10.1007/s00259-021-05565-z.Peer-Reviewed Original ResearchConceptsBrain sectionsMouse brain sectionsEnzyme occupancyBrain-specific enzymeBrain cholesterol homeostasisTreatment of seizuresWild-type miceAdult rhesus macaquesDose-dependent mannerWarrants further studyLogan graphical analysisEpileptic encephalopathySoticlestatBaseline scanAutoradiography studiesPreclinical characterizationLassen plotPreclinical validationBrain regionsCortical regionsPET studiesRhesus macaquesCholesterol homeostasisPET imagingARG studyPerformance Evaluation of Amplitude and Phase Respiratory Gating Methods on Continuous-Bed-Motion Whole-Body PET Studies
Tsai Y, Lu Y, Wu J, Liu H, Schleyer P, Casey M, Liu C. Performance Evaluation of Amplitude and Phase Respiratory Gating Methods on Continuous-Bed-Motion Whole-Body PET Studies. IEEE Transactions On Radiation And Plasma Medical Sciences 2021, 6: 415-420. DOI: 10.1109/trpms.2021.3075383.Peer-Reviewed Original ResearchSynthesis and Characterization of [18F]JNJ-46356479 as the First 18F-Labeled PET Imaging Ligand for Metabotropic Glutamate Receptor 2
Yuan G, Guehl N, Zheng B, Qu X, Moon S, Dhaynaut M, Shoup T, Afshar S, Kang H, Zhang Z, El Fakhri G, Normandin M, Brownell A. Synthesis and Characterization of [18F]JNJ-46356479 as the First 18F-Labeled PET Imaging Ligand for Metabotropic Glutamate Receptor 2. Molecular Imaging And Biology 2021, 23: 527-536. PMID: 33559035, PMCID: PMC8277681, DOI: 10.1007/s11307-021-01586-0.Peer-Reviewed Original ResearchConceptsNon-human primatesIn vivo PET imaging studiesNucleus accumbensGlutamate receptor 2PET imaging ligandsImaging ligandsParietal cortexBrain regionsPET imaging studiesPET radioligandIn vivo PET imaging experimentsVolume of distributionMGluR2C57BL/6 J micePET imaging experimentsPET studiesBrainSprague-Dawley ratsAlzheimer's diseaseBrain permeabilityPre-treatment studyImaging studiesDisordersRat studiesReversible kinetics
2020
Neuroimaging of Obsessive-Compulsive Disorder: Insights into Serotonergic Mechanisms
Lissemore J, Booij L, Leyton M, Gravel P, Sookman D, Nordahl T, Benkelfat C. Neuroimaging of Obsessive-Compulsive Disorder: Insights into Serotonergic Mechanisms. 2020, 457-478. DOI: 10.1007/978-3-030-57231-0_13.Peer-Reviewed Original ResearchSelective serotonin reuptake inhibitorsObsessive-compulsive disorderSerotonin synthesis capacityPositron emission tomographyHealthy controlsPET studiesOCD patientsSerotonin reuptake inhibitorsMost PET studiesBorderline personality disorderCognitive behavior therapySymptom onsetSerotonergic mechanismsClinical benefitSerotonergic toneSerotonergic alterationsSynthesis capacityEmission tomographySuicide attemptsSerotonin transporterPersonality disorderBehavior therapyGroup differencesDisordersPatientsAssessment of population-based input functions for Patlak imaging of whole body dynamic 18F-FDG PET
Naganawa M, Gallezot JD, Shah V, Mulnix T, Young C, Dias M, Chen MK, Smith AM, Carson RE. Assessment of population-based input functions for Patlak imaging of whole body dynamic 18F-FDG PET. EJNMMI Physics 2020, 7: 67. PMID: 33226522, PMCID: PMC7683759, DOI: 10.1186/s40658-020-00330-x.Peer-Reviewed Original ResearchPopulation-based input functionImage-derived input functionInitial distribution volumeArterial input functionInjected doseBlood samplingWhole bodyStandard arterial input functionInitial plasma concentrationsArterial blood samplingOncological patientsPlasma concentrationsGold standard methodDistribution volumePET studiesPET imagingSubject heightInput functionAUCAUC valuesTest-retest dataClinical environmentLater time windowKi valuesImagingPET Imaging of Synaptic Vesicle Protein 2A
Finnema S, Li S, Cai Z, Naganawa M, Chen M, Matuskey D, Nabulsi N, Esterlis I, Holmes S, Radhakrishnan R, Toyonaga T, Huang Y, Carson R. PET Imaging of Synaptic Vesicle Protein 2A. 2020, 993-1019. DOI: 10.1007/978-3-030-53176-8_29.ChaptersSynaptic vesicle protein 2APositron emission tomographyAntiepileptic drug levetiracetamInitial PET studiesPET imagingPET studiesSynaptic densityDrug levetiracetamHigh-affinity SV2A ligandsBrain regionsSynaptic density lossNeuropathological diseasesDisease-modifying therapiesLarge patient cohortMajor depressive disorderProtein 2APET imaging resultsPosttraumatic stress disorderPatient groupPatient cohortDepressive disorderClinical valueParkinson's diseaseEfficacy assessmentSynaptic vesicle proteinsNondisplaceable Binding Is a Potential Confounding Factor in 11C-PBR28 Translocator Protein PET Studies
Laurell G, Plavén-Sigray P, Jucaite A, Varrone A, Cosgrove KP, Svarer C, Knudsen G, Consortium K, Ogden R, Zanderigo F, Cervenka S, Hillmer A, Schain M. Nondisplaceable Binding Is a Potential Confounding Factor in 11C-PBR28 Translocator Protein PET Studies. Journal Of Nuclear Medicine 2020, 62: 412-417. PMID: 32680926, PMCID: PMC8049343, DOI: 10.2967/jnumed.120.243717.Peer-Reviewed Original ResearchConceptsAlcohol use disorderDistribution volumePET studiesParkinson's diseaseFirst-episode psychosis patientsTranslocator proteinAdministration of lipopolysaccharideNondisplaceable bindingFirst-episode psychosisPotential confounding factorsTotal distribution volumeC-PBR28Patient groupPsychosis patientsLipopolysaccharide challengeClinical studiesOutcome measuresTSPO PET studiesUse disordersPET ligandConfounding factorsCorresponding controlsDiseaseDisordersGroupTobacco Smoking in People Is Not Associated with Altered 18-kDa Translocator Protein Levels: A PET Study
Hillmer AT, Matuskey D, Huang Y, Nabulsi N, Ropchan J, Carson RE, O'Malley SS, Cosgrove KP. Tobacco Smoking in People Is Not Associated with Altered 18-kDa Translocator Protein Levels: A PET Study. Journal Of Nuclear Medicine 2020, 61: 1200-1204. PMID: 32005773, PMCID: PMC7413239, DOI: 10.2967/jnumed.119.237735.Peer-Reviewed Original ResearchConceptsTobacco smokingTobacco smokersTSPO levelsImmune systemPET studiesBrain immune systemBrain TSPO levelsPrimary immunocompetent cellsPrevious PET studiesTranslocator proteinTranslocator protein (TSPO) levelsInflammatory effectsImmunocompetent cellsArterial bloodTobacco smokePET scansNonsmokersSmokersRadiotracer concentrationMedium effect sizeSmokingPET imagingBrainProtein levelsSignificant differences
2019
Norepinephrine transporter availability in brown fat is reduced in obesity: a human PET study with [11C] MRB
Sanchez-Rangel E, Gallezot JD, Yeckel CW, Lam W, Belfort-DeAguiar R, Chen MK, Carson RE, Sherwin R, Hwang JJ. Norepinephrine transporter availability in brown fat is reduced in obesity: a human PET study with [11C] MRB. International Journal Of Obesity 2019, 44: 964-967. PMID: 31636373, PMCID: PMC7259982, DOI: 10.1038/s41366-019-0471-4.Peer-Reviewed Original ResearchConceptsBrown adipose tissueDetectable brown adipose tissueDistribution volume ratioMultilinear reference tissue model 2Norepinephrine transporterSympathetic innervationNorepinephrine transporter availabilityHuman brown adipose tissueDense sympathetic innervationPET-CT imagingReference tissue model 2Human PET studiesSupraclavicular regionCaucasian womenTransporter availabilityOccipital cortexObesityTherapeutic targetAdipose tissueBrown fatPET studiesWomenInnervationSelective ligandsEnergy-dissipating properties
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply